Publication | Closed Access

Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial

MedicineMetronomic TherapyGynecologyPathologyGestational Trophoblastic NeoplasiaCap 01Cancer TreatmentOncologyRadiation OncologyMolecular OncologyHigh-risk Chemorefractory